"How to reconstitute tirzepatide" is a question the drug's own label never has to answer. Every approved tirzepatide product is a solution, sold ready to inject; nothing Lilly makes is mixed. Reconstitution arises only for tirzepatide sold as a powder — research-labelled vials and some compounded preparations — which is outside the label by definition. This page reports what the record contains, sets out the concentration arithmetic in the third person, and uses the label's own presentations to show where that arithmetic goes wrong. It is not an instruction to prepare or use anything. How brands appear on this site is set out on our disclosure page.
Every approved product is already a solution
The Zepbound prescribing information (Eli Lilly, openFDA set ID 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective 2026-08-28) describes four presentations, all a "clear, colorless to slightly yellow solution":
| Presentation | Strengths | Volume per dose | Concentration |
|---|---|---|---|
| Single-dose pen or vial | 2.5, 5, 7.5, 10, 12.5, 15 mg | 0.5 mL | 5 to 30 mg/mL |
| Multi-dose vial (4 doses) | 10 to 60 mg per vial | 0.6 mL, every strength | 4.17 to 25 mg/mL |
| Single-patient-use KwikPen (4 doses) | 10 to 60 mg per pen | set by the pen | 4.17 to 25 mg/mL |
Mounjaro, the diabetes brand of the same molecule, is sold as the same kinds of solution. FDA's NDC directory, queried through openFDA on 2026-09-24, holds 168 tirzepatide listings: 72 bulk-ingredient powders from about thirty firms, 42 "drug for further processing" solutions, and 54 human prescription listings — every one of those 54 an injectable solution, from Lilly or a repackager. A bulk listing records that a firm told FDA it makes the ingredient; it is not a finished product and not an approval. What "research use only" does and does not mean is on our research-use-only explainer.
The label's design choice, and why it matters for the arithmetic
The multi-dose vial is the part of the label worth reading closely. Lilly holds the injected volume constant at 0.6 mL and changes the concentration between vials: 4.17 mg/mL in the 2.5 mg vial, 25 mg/mL in the 15 mg vial. Someone stepping up a dose moves to a different vial and draws the same volume.
Reconstituting powder does the opposite. One vial, mixed once, has one concentration, so each dose step means drawing a different volume. That is the step where units and milligrams get confused, and it is the class of error FDA describes: its page on unapproved GLP-1 drugs, current as of 2026-09-01, reports adverse events, "some requiring hospitalization", that "may be related to dosing errors" with compounded injectable semaglutide, and events that may be related to compounded semaglutide or tirzepatide "in doses beyond what is in the FDA-approved drug label" (FDA). As of 2026-05-31 FDA had received more than 730 adverse-event reports associated with compounded tirzepatide.
The procedure, as labels for other products describe it
With no tirzepatide powder on any label, the nearest official description of reconstitution comes from approved lyophilized peptides, which specify the diluent, the exact volume, to swirl rather than shake, to inspect for particles, and when to discard. Our general reconstitution page sets out those steps as one such label states them. They describe how the procedure is done for that product; none of its numbers transfers to tirzepatide.
The arithmetic
The arithmetic is the same for every powder: milligrams in the vial ÷ millilitres of diluent = mg/mL, and one unit on a U-100 insulin syringe is 0.01 mL. Applied to the label's own dose steps, for a hypothetical 10 mg vial mixed three ways:
| Label dose step | 10 mg in 1 mL (10 mg/mL) | 10 mg in 2 mL (5 mg/mL) | 10 mg in 4 mL (2.5 mg/mL) | Approved multi-dose vial |
|---|---|---|---|---|
| 2.5 mg | 25 units | 50 units | 100 units | 0.6 mL at 4.17 mg/mL |
| 5 mg | 50 units | 100 units | 200 units | 0.6 mL at 8.33 mg/mL |
| 7.5 mg | 75 units | 150 units | 300 units | 0.6 mL at 12.5 mg/mL |
| 10 mg | 100 units | 200 units | 400 units | 0.6 mL at 16.7 mg/mL |
| 15 mg | 150 units | 300 units | 600 units | 0.6 mL at 25 mg/mL |
Three things follow, and they are arithmetic, not advice. The same milligram amount is a different unit figure in every column, so a unit number copied from a source that mixed a different vial or volume is wrong by the ratio of the two concentrations — a factor of four between the first and third columns. The label's own dose steps run past one 100-unit syringe at the lower concentrations. And a 10 mg vial does not hold one 15 mg amount at any volume. The dose steps themselves, and how the label escalates between them, are on our tirzepatide dosage page; Medibact Guides' tirzepatide reconstitution page carries a fuller water-volume grid.
The number the arithmetic starts from
Every figure in that table assumes the vial holds what its label says. For an approved Lilly product that is a manufacturing specification FDA reviewed. For a powder vial sold outside the label it is a claim, and the only check on it is a content assay: a certificate that reports purity alone says what fraction of the peptide is tirzepatide, not how many milligrams are in the vial. The difference, and why it matters more than purity for this arithmetic, is on our peptide testing page; the same point is worked through with published test counts on our retatrutide reconstitution page.
FDA adds a question about the molecule itself. For semaglutide it has warned that salt forms such as semaglutide sodium and acetate "are different active ingredients than are used in the approved drugs"; the same question applies to any tirzepatide powder whose salt form its label does not state, and a salt changes how many milligrams of the active molecule a stated weight contains.
Storage after mixing
No regulator has published stability data for tirzepatide powder mixed in bacteriostatic or sterile water. The only in-use figures in the record belong to Lilly's solutions: an opened multi-dose vial or KwikPen is discarded "after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it", and single-dose pens and vials may spend up to 21 days unrefrigerated. Those are properties of those formulations. What the labels say about peptide solutions in general is on our peptide storage page.
Where compounding stands
FDA declared the tirzepatide injection shortage resolved on October 2, 2024 and reaffirmed it on December 19, 2024. Its enforcement discretion ended on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities; FDA's policy page, current as of 2026-04-01, notes that tirzepatide is on neither the 503B bulks list nor the shortage list (FDA). What separates the two kinds of compounder is explained on our 503A vs 503B page. FDA has also warned companies selling tirzepatide labelled "for research purposes" or "not for human consumption".
What is not known
Tirzepatide's stability in bacteriostatic water; the salt form and actual content of any given powder vial until an assay says so; and whether a mixed powder behaves like Lilly's solution once injected. Nothing on this page is a recommendation; a decision about tirzepatide, and about the dose, belongs with a prescriber.
Sources and dates
Read 2026-09-24: Zepbound prescribing information via openFDA (dosage forms and strengths, how supplied, storage and handling, dosage and administration; effective 2026-08-28) and the openFDA label listing for tirzepatide (Zepbound and Mounjaro, Lilly and repackager copies); openFDA NDC directory, 168 tirzepatide listings read in two pages; FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize" (current as of 2026-04-01); FDA, "FDA's concerns with unapproved GLP-1 drugs used for weight loss" (current as of 2026-09-01). Corrections go to the contact page.